These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26712054)

  • 1. Occult HBV reactivation induced by ibrutinib treatment: a case report.
    de Jésus Ngoma P; Kabamba B; Dahlqvist G; Sempoux C; Lanthier N; Shindano T; Van Den Neste E; Horsmans Y
    Acta Gastroenterol Belg; 2015 Dec; 78(4):424-6. PubMed ID: 26712054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis.
    Innocenti I; Morelli F; Autore F; Corbingi A; Pasquale R; Sorà F; Pompili M; Laurenti L
    Leuk Lymphoma; 2019 May; 60(5):1340-1342. PubMed ID: 30730231
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe hepatitis B virus reactivation related to ibrutinib monotherapy.
    Herishanu Y; Katchman H; Polliack A
    Ann Hematol; 2017 Apr; 96(4):689-690. PubMed ID: 28058492
    [No Abstract]   [Full Text] [Related]  

  • 4. Is HBV prophylaxis required during CLL treatment with ibrutinib?
    Tedeschi A; Frustaci AM; Mazzucchelli M; Cairoli R; Montillo M
    Leuk Lymphoma; 2017 Dec; 58(12):2966-2968. PubMed ID: 28535112
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
    Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
    Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients.
    Molica S; Levato L; Mirabelli R; Tedeschi A; Lentini M
    Leuk Lymphoma; 2018 Nov; 59(11):2734-2736. PubMed ID: 29465275
    [No Abstract]   [Full Text] [Related]  

  • 7. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
    Michallet AS; Dilhuydy MS; Subtil F; Rouille V; Mahe B; Laribi K; Villemagne B; Salles G; Tournilhac O; Delmer A; Portois C; Pegourie B; Leblond V; Tomowiak C; de Guibert S; Orsini F; Banos A; Carassou P; Cartron G; Fornecker LM; Ysebaert L; Dartigeas C; Truchan Graczyk M; Vilque JP; Aurran T; Cymbalista F; Lepretre S; Lévy V; Nguyen-Khac F; Le Garff-Tavernier M; Aanei C; Ticchioni M; Letestu R; Feugier P
    Lancet Haematol; 2019 Sep; 6(9):e470-e479. PubMed ID: 31324600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
    Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive aspergillosis with pulmonary and central nervous system involvement during ibrutinib therapy for relapsed chronic lymphocytic leukaemia: case report.
    Peri AM; Bisi L; Cappelletti A; Colella E; Verga L; Borella C; Foresti S; Migliorino GM; Gori A; Bandera A
    Clin Microbiol Infect; 2018 Jul; 24(7):785-786. PubMed ID: 29427802
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk of hepatitis B virus reactivation in patients treated with ibrutinib.
    Hammond SP; Chen K; Pandit A; Davids MS; Issa NC; Marty FM
    Blood; 2018 Apr; 131(17):1987-1989. PubMed ID: 29490923
    [No Abstract]   [Full Text] [Related]  

  • 11. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
    Bennett CL; Berger JR; Sartor O; Carson KR; Hrushesky WJ; Georgantopoulos P; Raisch DW; Norris LB; Armitage JO
    Br J Haematol; 2018 Jan; 180(2):301-304. PubMed ID: 27649938
    [No Abstract]   [Full Text] [Related]  

  • 12. Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.
    Ruchlemer R; Ben-Ami R; Bar-Meir M; Brown JR; Malphettes M; Mous R; Tonino SH; Soussain C; Barzic N; Messina JA; Jain P; Cohen R; Hill B; Mulligan SP; Nijland M; Herishanu Y; Benjamini O; Tadmor T; Okamoto K; Arthurs B; Gottesman B; Kater AP; Talha M; Eichhorst B; Korem M; Bogot N; De Boer F; Rowe JM; Lachish T
    Mycoses; 2019 Dec; 62(12):1140-1147. PubMed ID: 31520441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib.
    Sun C; Gao J; Couzens L; Tian X; Farooqui MZ; Eichelberger MC; Wiestner A
    JAMA Oncol; 2016 Dec; 2(12):1656-1657. PubMed ID: 27533065
    [No Abstract]   [Full Text] [Related]  

  • 14. Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia.
    Dasanu CA
    J Oncol Pharm Pract; 2019 Jun; 25(4):1003-1005. PubMed ID: 29720040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia.
    Peri AM; Rossio R; Tafuri F; Benzecry V; Grancini A; Reda G; Bandera A; Peyvandi F
    Ann Hematol; 2019 Dec; 98(12):2847-2849. PubMed ID: 31741032
    [No Abstract]   [Full Text] [Related]  

  • 16. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
    Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
    Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.
    Varughese T; Taur Y; Cohen N; Palomba ML; Seo SK; Hohl TM; Redelman-Sidi G
    Clin Infect Dis; 2018 Aug; 67(5):687-692. PubMed ID: 29509845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malakoplakia of the Urinary Bladder in a Patient with Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: A Case Report.
    Sachanas S; Pangalis GA; Karouzakis P; Koulieris E; Moschogiannis M; Kalpadakis C; Yiakoumis X; Rontogianni D
    Anticancer Res; 2016 Sep; 36(9):4759-62. PubMed ID: 27630324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia.
    Sato R; Jacob J; Gaballa S
    Leuk Lymphoma; 2018 Jul; 59(7):1738-1741. PubMed ID: 29081253
    [No Abstract]   [Full Text] [Related]  

  • 20. Ibrutinib and rituximab for chronic lymphocytic leukaemia.
    Stirrups R
    Lancet Oncol; 2019 Sep; 20(9):e471. PubMed ID: 31402323
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.